Home › News › Biogen Idec/Elan's Antegren will Radically Alter the Multiple Sclerosis Drug Market
Biogen Idec/Elan's Antegren will Radically Alter the Multiple Sclerosis Drug Market
Publish date: 13 Sep, 2004
Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that Biogen Idec/Elan's Antegren will radically alter the multiple sclerosis drug market. According to the new Pharmacor study entitled Multiple Sclerosis, Antegren, a monoclonal antibody, will account for one-third of the market in 2013. The drug received FDA priority review in July 2004 and is expected to launch in early 2005.
"Sales of Antegren will be driven by the drug's efficacy and more- convenient dosing over currently available therapies," said Andrea Witt, Ph.D., analyst at Decision Resources. "Antegren's sales will rival that of all the IFN-beta therapies combined in 2013. Thought leaders are uniformly excited about the arrival of Antegren, which they anticipate will be an effective drug with few side effects."
About Multiple Sclerosis
Multiple sclerosis is a disease of the central nervous system characterized by the destruction of the myelin sheath surrounding neurons, resulting in the formation of "plaques." The disease is a progressive and usually fluctuating condition with exacerbations (patients feeling worse) and remissions (patients feeling better) over many decades. Multiple sclerosis is three times more common in women than in men, and patients are usually diagnosed as young adults.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.
Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-
2563, emarshall@dresources.com
Pain Drug Market Offers Biopharmaceutical Companies Significant Commercial Opportunity